2613MO Identifying biomarkers of response to first-line nivolumab plus ipilimumab therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) enrolled in the COSMIC 313 trial. - Simsek, B.; Niman, S.M.; El Ahmar, N.; Mohanna, R.A.; Delcea, A.; De Oliveira, G.R.; Laimon, Y.N.; Ascione, L.; Xie, W.; Braun, D.A.; Sun, M.; Saad, E.; et al. (Annals of Oncology, 2025)